Prospects for the next wave of replacement medicines for those who are old-fashioned, urologists and urologists clearly need to consider whether it is wise to pursue the new therapeutics, nor is the question something on which there is consensus, so they need to understand what the best paths will be to futureing their learning in the complex field of pharmacology.
Making possible their decision will be the first specification of its kind, as they consider that this replacement drug is long-acting, and having been developed and tested, it must be commended. In fact, the same physical properties and a wide range of pharmacology (and the clinical role of urology) than that of their first idealized big tubular capsule are just what they are looking for.
The prescription for long-acting candidates is that these are highly effective once-daily medications that compete closely in dose with cheap oral anti-androgens that have been gaining in favor. We expect to see them account for at least 5% of the global market in a decade. Moreover, the EMA has given the new developmental pathway the thumbs up, encouraging any confidence of future transition to possible commercial activity.
It is then that we now must manage patient choice and patient preference. While we cannot know for sure what may change in the way we use anti-androgens, there is some knowledge of their effectiveness and tolerability. We have also learned that patient choice is of course very important for all medicines and should not be taken for granted.
The new soluble agent (UACIA) offers the possibility of the shortest dosing interval yet known for a drug of its kind, and one that becomes the direction of a whole new class of meds. The benefit of the saline solution we have developed is that it is a variable fluid that will be not only controlled but labeled with only the lowest level of activity for the duration of the drug to be administered (well under an hour). Not only does that address the difficulty of patient choice, but also minimizes any potential use for longer acting UACIA.
The desire of the large pharmaceutical companies to assure continued activities in the therapy of specific renal conditions and complex vascular problems will seem acute. However, clinicians in urology have never been known for their singular focus on particular conditions.
What care and judgment should be needed to engage such action in patients may be the biggest challenge of all. However, with the new therapeutic-level protocol that we will soon share with clinicians, all will be on the same page. It will be important to give physicians the best clinical information possible and to encourage their dissemination in order to increase widespread research to ensure that knowledge regarding the nomenclature of specific conditions is relayed on the level which will be best for the patients.
For the next few years, we will definitely see a measure of acceptance of new approaches to renal medicine and perhaps demand for the available options to embrace them, though it may well come as something of a surprise to the roughly half the population of the US that still suffers from and/or lives with kidney failure.
First Published: Sep 08, 2018 12:27 IST